deramiocel
Cell therapy
Also known as CAP-1002
Evidence outlook · regulatory review
Duchenne Muscular Dystrophy: application under FDA review, decision date 2026-11-22
PDUFA target action date set for deramiocel BLA (2026-08-22). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
Latest reported trial: HOPE-3 (NCT05126758) · Phase 3 · met primary endpoint · grade pending
Also in development:Heart Failure · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
HOPE-3 NCT05126758 · Duchenne Muscular Dystrophy Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT05126758 | 3 | Change in the upper limb function (At Month 12) 2025-06-18 | HOPE-3 (NCT05126758), primary endpoint PUL v2.0 total score: deramiocel showed 54% slowing of disease progression vs placebo; p=0.029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other Cardiac cell therapy drugs
CardiAMP, HiCM-188 (allogeneic iPSC-cardiomyocytes), ADR-002K, HS-001, HucMSC intramyocardial therapy and 2 more. Compare all 8 Cardiac cell therapy drugs
7 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Duchenne Muscular Dystrophy: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Deramiocel: this drug | Phase 3 | Cell therapy | Cardiac cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| Givinostat | Approved | Small molecule | HDAC | Reliable signal | NCT02851797: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment (Baseline and 18 months): Givinostat 1.27 seconds (Standard Error 0.04) | Placebo 1.48 seconds (Standard Error 0.058) | |
| RGX-202 | Phase 2/3 | Gene therapy / editing | Dystrophin (microdystrophin transgene) | not yet graded | No reviewed efficacy summary in this indication | |
| Delpacibart Zotadirsen | Phase 2 | RNA / oligonucleotide | DMD exon 44 | not yet graded | No reviewed efficacy summary in this indication | |
| Bampidirsen | Phase 1/2 | RNA / oligonucleotide | DMD exon 53 | not yet graded | No reviewed efficacy summary in this indication | |
| Nivudirsen (BMN 351) | Phase 1/2 | RNA / oligonucleotide | DMD exon 51 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(7)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent